Therapeutic Asset Ratings

91,564 assets7,904 sponsors3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Adriamycin Lymphoma	Beth Israel Deaconess Medical Center	P3	BB (69)
Adriamycin Ovarian Clear Cell Adenocarcinoma	National Cancer Institute (NCI)	P3	BB (69)
Adriamycin Ovarian Endometrioid Adenocarcinoma	National Cancer Institute (NCI)	P3	BB (69)
Apitegromab Neuromuscular Disease	Scholar Rock, Inc.	P3	BB (69)
ARG Sickle Cell Disease	Tanta University	P3	BB (69)
Aspirin Breast Carcinoma	Mayo Clinic	P3	BB (69)
Aspirin Lynch Syndrome	M.D. Anderson Cancer Center	P3	BB (69)
Atorvastatin Renal Cell Carcinoma	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P3	BB (69)
Autologous Cd34+ Cells Isolated From Mobilised Peripheral Blood By Positive Selection, Modified By Crispr/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats/Crispr-Associated Protein 9) Mediated Gene Editing Consisting Of A Guide Rna (Grna) Introduced Transiently As Ribonucleoprotein (Rnp) Complex, Targeting The Erythroid Lineage-Specific Enhancer Region Of Bcl11A (B-Cell Lymphoma/Leukemia 11A). The Site-Specific Cleavage By Cas9 Forms A Double Strand Break (Dsb), Which Is Subsequently Repaired By Nonhomologous End-Joining (Nhej), Leading To The Transcriptional Repression Of Bcl11A, A Repressor Of ?-Globin Gene Transcription Disease Of Genetic Or Genomic Mechanism	Vertex Pharmaceuticals Incorporated	P3	BB (69)
Axitinib Kidney Neoplasm	Pfizer	P3	BB (69)
Benzeneethanamine, N-Ethyl-?-Methyl-4-(Trifluoromethyl)-, Hydrochloride, (±)- Lennox-Gastaut Syndrome	University of Chicago	P3	BB (69)
Bicalutamide Prostate Adenocarcinoma	OHSU Knight Cancer Institute	P3	BB (69)
Capecitabine Gastroesophageal Junction Adenocarcinoma	I-Mab Biopharma US Limited	P3	BB (69)
Capecitabine Metastatic Neoplasm	University of Southern California	P3	BB (69)
Carboplatin Adenosquamous Lung Carcinoma	NRG Oncology	P3	BB (69)
Cediranib Fallopian Tube Transitional Cell Carcinoma	National Cancer Institute (NCI)	P3	BB (69)
Cediranib Ovarian Seromucinous Carcinoma	National Cancer Institute (NCI)	P3	BB (69)
Cediranib Ovarian Transitional Cell Carcinoma	National Cancer Institute (NCI)	P3	BB (69)
Cediranib Undifferentiated Ovarian Carcinoma	National Cancer Institute (NCI)	P3	BB (69)
Cediranib Hodgkins Lymphoma	M.D. Anderson Cancer Center	P3	BB (69)
Ceralasertib Non-Small Cell Lung Carcinoma	Mario Negri Institute for Pharmacological Research	P3	BB (69)
Cetuximab Non-Small Cell Lung Carcinoma	Novartis Pharmaceuticals	P3	BB (69)
Chlorambucil B-Cell Chronic Lymphocytic Leukemia	Janssen Research & Development, LLC	P3	BB (69)
Cis-Diamminedichloroplatinum Ii Non-Small Cell Squamous Lung Carcinoma	Gruppo Oncologico Italiano di Ricerca Clinica	P3	BB (69)
Cis-Diamminedichloroplatinum Ii Head And Neck Cancer	ImmunityBio, Inc.	P3	BB (69)

Showing 1876 to 1900 of 42,327 assets

PreviousPage 76 of 1694Next